JO
TSHA icon

John Overdeck’s Taysha Gene Therapies TSHA Stock Holding History

John Overdeck’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6M Sell
234,716
-507,365
-68% -$3M ﹤0.01% 3204
2026
Q1 		$3.32M Buy
742,081
+390,955
+111% +$1.82M ﹤0.01% 2360
2025
Q4 		$1.93M Buy
351,126
+285,021
+431% +$1.38M ﹤0.01% 2464
2025
Q3 		$216K Buy
66,105
+33,423
+102% +$94.6K ﹤0.01% 3351
2025
Q2 		$75.5K Buy
+32,682
New +$71K ﹤0.01% 3029
2025
Q1 		– Sell
-12,300
Closed -$21.3K – 3497
2024
Q4 		$21.3K Buy
+12,300
New +$25.5K ﹤0.01% 3102
2024
Q2 		– Sell
-121,517
Closed -$349K – 3336
2024
Q1 		$349K Sell
121,517
-15,456
-11% -$32.2K ﹤0.01% 2492
2023
Q4 		$242K Buy
+136,973
New +$273K ﹤0.01% 2766
2022
Q4 		– Sell
-43,378
Closed -$84K – 3092
2022
Q3 		$84K Sell
43,378
-24,266
-36% -$88.1K ﹤0.01% 2253
2022
Q2 		$252K Sell
67,644
-114,264
-63% -$453K ﹤0.01% 2084
2022
Q1 		$1.19M Buy
181,908
+112,679
+163% +$842K ﹤0.01% 1634
2021
Q4 		$807K Buy
+69,229
New +$1.04M ﹤0.01% 2755

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's TSHA Position: Q2 2026 in Review

John Overdeck reduced its Taysha Gene Therapies (TSHA) stake by 68% in Q2 2026, selling an estimated $3M and leaving 234,716 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3204.

John Overdeck first reported a position in TSHA in Q4 2021 and has held it in 12 quarters since. The position peaked at $3.32M in Q1 2026. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • John Overdeck held 234,716 shares of Taysha Gene Therapies worth $1.6M as of Q2 2026.
  • John Overdeck sold 507,365 Taysha Gene Therapies shares in Q2 2026, an estimated $3M.
  • Taysha Gene Therapies made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3204 holding.
  • John Overdeck first reported a position in Taysha Gene Therapies in Q4 2021 and has held it in 12 quarters since.
  • John Overdeck's Taysha Gene Therapies position peaked at $3.32M in Q1 2026.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.